Aislinn Antrim, Assistant Managing Editor from Pharmacy Times - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats		The Future of Immunotherapy in Breast Cancer Involves Engineered T-Cell Therapies, Better Prediction of Adverse Effects - 5 months ago Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer - 6 months ago Adding Pembrolizumab to Chemotherapy Increased Pathological Complete Response, Improved Residual Cancer Burden in Early-Stage, High-Risk ER+/HER2- Breast Cancer - 6 months ago Abemaciclib, Nonsteroidal Aromatase Inhibitor Extends Overall Survival for Patients With HR+, HER2- Advanced Breast Cancer - 6 months ago Study: Patients With PD-L1-Positive, High-Risk, ER+/HER2- Breast Cancer Can Achieve Substantial Complete Response Rates With Addition of Nivolumab - 6 months ago MONALEESA Pooled Analyses Show Quality of Life Is Maintained in Elderly Patients Receiving Ribociclib, Endocrine Therapy - 6 months ago New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations - 6 months ago Experts Say More Research Is Needed to Understand Obesity-Cancer Link - 6 months ago FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Treatments - 6 months ago FDA Issues Fast Track Designation to ADP101 for Mono-, Multi-Food Allergies - 6 months ago FDA Approves Tirzepatide for Chronic Weight Management - 6 months ago FDA Approves Secukinumab for Hidradenitis Suppurativa - 7 months ago Study Links Long COVID With Short Sleep Duration - 7 months ago FDA Approves Zilucoplan for Generalized Myasthenia Gravis in AChR Antibody-Positive Adults - 7 months ago Scholarship Program Aims to Improve Diversity, Equity in Pharmacy Field - 7 months ago FDA Approves Secukinumab as First Intravenous Interleukin-17A Antagonist for Rheumatic Diseases - 7 months ago Study Finds IVIG, Therapeutic Plasma Exchange Have Comparable Efficacy for Neurological Disorders - 8 months ago Survey Highlights Need for Improved Working Conditions, Communication in Pharmacies - 8 months ago Axicabtagene Ciloleucel Demonstrates High Response Rate in Relapsed/Refractory Large B-cell Lymphoma - 8 months ago Phase 3 Trial Reinforces Favorability of Roflumilast Cream 0.05% for Atopic Dermatitis in Children - 8 months ago Study: Shared Decision-Making in Cardiovascular Health is Infrequently Utilized, Despite Benefits - 8 months ago